These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 26980523

  • 1. Disturbances of cardiac wavelength and repolarization precede Torsade de Pointes and ventricular fibrillation in Langendorff perfused rabbit hearts.
    Hondeghem LM.
    Prog Biophys Mol Biol; 2016 May; 121(1):3-10. PubMed ID: 26980523
    [Abstract] [Full Text] [Related]

  • 2. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR, Yan GX, Gallacher DJ.
    J Pharmacol Toxicol Methods; 2013 May; 68(2):250-259. PubMed ID: 23337247
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs.
    Valentin JP, Hoffmann P, De Clerck F, Hammond TG, Hondeghem L.
    J Pharmacol Toxicol Methods; 2004 May; 49(3):171-81. PubMed ID: 15172013
    [Abstract] [Full Text] [Related]

  • 6. Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes.
    Ellermann C, Sterneberg M, Kochhäuser S, Dechering DG, Fehr M, Eckardt L, Frommeyer G.
    Europace; 2018 Oct 01; 20(10):1699-1706. PubMed ID: 29377987
    [Abstract] [Full Text] [Related]

  • 7. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic.
    Hondeghem LM, Carlsson L, Duker G.
    Circulation; 2001 Apr 17; 103(15):2004-13. PubMed ID: 11306531
    [Abstract] [Full Text] [Related]

  • 8. QT and TdP. QT: an unreliable predictor of proarrhythmia.
    Hondeghem LM.
    Acta Cardiol; 2008 Feb 17; 63(1):1-7. PubMed ID: 18372573
    [Abstract] [Full Text] [Related]

  • 9. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
    Hondeghem LM.
    J Cardiovasc Electrophysiol; 2006 Mar 17; 17(3):337-40. PubMed ID: 16643415
    [Abstract] [Full Text] [Related]

  • 10. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL, Pollard CE, Hammond TG, Valentin JP.
    J Pharmacol Toxicol Methods; 2005 Mar 17; 52(1):46-59. PubMed ID: 15975832
    [Abstract] [Full Text] [Related]

  • 11. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR, Vlaminckx E, Van de Water A, Rohrbacher J, Hermans A, Gallacher DJ.
    Eur J Pharmacol; 2006 Dec 28; 553(1-3):229-39. PubMed ID: 17054943
    [Abstract] [Full Text] [Related]

  • 12. TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability).
    Hondeghem LM.
    Novartis Found Symp; 2005 Dec 28; 266():235-44; discussion 244-50. PubMed ID: 16050272
    [Abstract] [Full Text] [Related]

  • 13. Oscillations of cardiac wave length and proarrhythmia.
    Hondeghem LM, Dumotier B, Traebert M.
    Naunyn Schmiedebergs Arch Pharmacol; 2010 Oct 28; 382(4):367-76. PubMed ID: 20803191
    [Abstract] [Full Text] [Related]

  • 14. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
    Lu HR, Gallacher DJ, Yan GX.
    J Pharmacol Toxicol Methods; 2016 Oct 28; 81():151-60. PubMed ID: 27374776
    [Abstract] [Full Text] [Related]

  • 15. Optical mapping of drug-induced polymorphic arrhythmias and torsade de pointes in the isolated rabbit heart.
    Asano Y, Davidenko JM, Baxter WT, Gray RA, Jalife J.
    J Am Coll Cardiol; 1997 Mar 15; 29(4):831-42. PubMed ID: 9091531
    [Abstract] [Full Text] [Related]

  • 16. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
    Said TH, Wilson LD, Jeyaraj D, Fossa AA, Rosenbaum DS.
    J Cardiovasc Pharmacol; 2012 Aug 15; 60(2):165-71. PubMed ID: 22561361
    [Abstract] [Full Text] [Related]

  • 17. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
    Lu HR, Hermans AN, Gallacher DJ.
    Br J Pharmacol; 2012 Jun 15; 166(4):1490-502. PubMed ID: 22300168
    [Abstract] [Full Text] [Related]

  • 18. Drug-Induced QT Prolongation and Torsades de Pointes: An All-Exclusive Relationship or Time for an Amicable Separation?
    Hondeghem LM.
    Drug Saf; 2018 Jan 15; 41(1):11-17. PubMed ID: 28853038
    [Abstract] [Full Text] [Related]

  • 19. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
    Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G.
    Cardiovasc Res; 1993 Dec 15; 27(12):2186-93. PubMed ID: 8313427
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block.
    Milberg P, Ramtin S, Mönnig G, Osada N, Wasmer K, Breithardt G, Haverkamp W, Eckardt L.
    J Cardiovasc Pharmacol; 2004 Sep 15; 44(3):278-86. PubMed ID: 15475823
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.